{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:09:21Z","timestamp":1764493761963},"reference-count":20,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.ejca.2013.07.147","type":"journal-article","created":{"date-parts":[[2013,8,19]],"date-time":"2013-08-19T08:45:58Z","timestamp":1376901958000},"page":"3666-3670","source":"Crossref","is-referenced-by-count":16,"title":["Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis"],"prefix":"10.1016","volume":"49","author":[{"given":"David","family":"Ghez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Micol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Pasquier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Auger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Saada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Spentchian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Ianotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Henri","family":"Bourhis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anelyse","family":"Bennaceur-Griscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Terr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Castaigne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Rigaudeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Rousselot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"de Botton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejca.2013.07.147_b0005","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N","article-title":"Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2013.07.147_b0010","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2013.07.147_b0015","first-page":"509","article-title":"Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic leukemia working party of the european group for bone marrow transplantation","volume":"12","author":"Gratwohl","year":"1993","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.ejca.2013.07.147_b0020","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.ejca.2013.07.147_b0025","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejca.2013.07.147_b0030","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ejca.2013.07.147_b0035","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejca.2013.07.147_b0040","first-page":"1213","article-title":"De MM, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia","volume":"88","author":"Sureda","year":"2003","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.ejca.2013.07.147_b0045","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2013.07.147_b0050","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2010.11.004","article-title":"The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)","volume":"35","author":"Deau","year":"2011","journal-title":"Leuk Res"},{"issue":"8","key":"10.1016\/j.ejca.2013.07.147_b0055","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.147_b0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","article-title":"A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.ejca.2013.07.147_b0065","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/sj.leu.2400796","article-title":"Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia","volume":"11","author":"Kantarjian","year":"1997","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejca.2013.07.147_b0070","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2019deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2013.07.147_b0075","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2013.07.147_b0080","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.3324\/haematol.2009.015693","article-title":"Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells","volume":"95","author":"Janssen","year":"2010","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejca.2013.07.147_b0085","doi-asserted-by":"crossref","first-page":"e22110","DOI":"10.1371\/journal.pone.0022110","article-title":"Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia","volume":"6","author":"Jelinek","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejca.2013.07.147_b0090","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3892\/ol.2011.419","article-title":"Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis","volume":"3","author":"Uehara","year":"2012","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.ejca.2013.07.147_b0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccr.2011.12.020","article-title":"Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib","volume":"21","author":"Li","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.ejca.2013.07.147_b0100","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccr.2010.03.011","article-title":"Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate","volume":"17","author":"Zhang","year":"2010","journal-title":"Cancer Cell"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913007326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804913007326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T05:43:28Z","timestamp":1563687808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804913007326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0959804913007326"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2013.07.147","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}